Selected research
Market Structure
Global Anti Obesity Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti Obesity Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Anti Obesity Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti Obesity Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti Obesity Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti Obesity Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti Obesity Drugs include Wanhan Pharma, ZENIN Biotechnology, Teva, Novartis, Roche, Lunan Pharma, Eli Lilly, VIVUS and Pharscin Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Anti Obesity Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti Obesity Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti Obesity Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Anti Obesity Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti Obesity Drugs Segment by Company
Wanhan Pharma
ZENIN Biotechnology
Teva
Novartis
Roche
Lunan Pharma
Eli Lilly
VIVUS
Pharscin Pharma
Novo Nordisk
Lupin Laboratories
iNova Pharmaceuticals
Hypera Pharma
GlaxoSmithKline
Alvogen
Anti Obesity Drugs Segment by Type
Injection
Oral
Anti Obesity Drugs Segment by Application
Hospital
Retail Pharmacy
Other
Anti Obesity Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti Obesity Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti Obesity Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti Obesity Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Anti Obesity Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti Obesity Drugs industry.
Chapter 3: Detailed analysis of Anti Obesity Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti Obesity Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Oral
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Wanhan Pharma
- ZENIN Biotechnology
- Teva
- Novartis
- Roche
- Lunan Pharma
- Eli Lilly
- VIVUS
- Pharscin Pharma
- Novo Nordisk
- Lupin Laboratories
- iNova Pharmaceuticals
- Hypera Pharma
- GlaxoSmithKline
- Alvogen
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Anti Obesity Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Injection
- 1.2.3 Oral
- 1.3 Market Analysis by Application
- 1.3.1 Global Anti Obesity Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Retail Pharmacy
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Anti Obesity Drugs Growth Trends by Region
- 1.5.1 Global Anti Obesity Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Anti Obesity Drugs Market Size by Region (2021-2026)
- 1.5.3 Anti Obesity Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Anti Obesity Drugs Market Dynamics
- 2.1 Anti Obesity Drugs Industry Trends
- 2.2 Anti Obesity Drugs Industry Drivers
- 2.3 Anti Obesity Drugs Industry Opportunities and Challenges
- 2.4 Anti Obesity Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Anti Obesity Drugs Revenue by Company (2021-2026)
- 3.2 Global Anti Obesity Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Anti Obesity Drugs Key Company Head office and Area Served
- 3.4 Global Anti Obesity Drugs Company, Product Type & Application
- 3.5 Global Anti Obesity Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Anti Obesity Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Anti Obesity Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Anti Obesity Drugs Tier 1, Tier 2, and Tier 3
4 Anti Obesity Drugs Market by Type
- 4.1 Global Anti Obesity Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Anti Obesity Drugs Market Size by Type (2021-2032)
- 4.3 Global Anti Obesity Drugs Market Size Share by Type (2021-2032)
5 Anti Obesity Drugs Market by Application
- 5.1 Global Anti Obesity Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Anti Obesity Drugs Market Size by Application (2021-2032)
- 5.3 Global Anti Obesity Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Wanhan Pharma
- 6.1.1 Wanhan Pharma Company Information
- 6.1.2 Wanhan Pharma Business Overview
- 6.1.3 Wanhan Pharma Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Wanhan Pharma Anti Obesity Drugs Product Portfolio
- 6.1.5 Wanhan Pharma Recent Developments
- 6.2 ZENIN Biotechnology
- 6.2.1 ZENIN Biotechnology Company Information
- 6.2.2 ZENIN Biotechnology Business Overview
- 6.2.3 ZENIN Biotechnology Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 ZENIN Biotechnology Anti Obesity Drugs Product Portfolio
- 6.2.5 ZENIN Biotechnology Recent Developments
- 6.3 Teva
- 6.3.1 Teva Company Information
- 6.3.2 Teva Business Overview
- 6.3.3 Teva Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Teva Anti Obesity Drugs Product Portfolio
- 6.3.5 Teva Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Novartis Anti Obesity Drugs Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Roche
- 6.5.1 Roche Company Information
- 6.5.2 Roche Business Overview
- 6.5.3 Roche Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Roche Anti Obesity Drugs Product Portfolio
- 6.5.5 Roche Recent Developments
- 6.6 Lunan Pharma
- 6.6.1 Lunan Pharma Company Information
- 6.6.2 Lunan Pharma Business Overview
- 6.6.3 Lunan Pharma Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Lunan Pharma Anti Obesity Drugs Product Portfolio
- 6.6.5 Lunan Pharma Recent Developments
- 6.7 Eli Lilly
- 6.7.1 Eli Lilly Company Information
- 6.7.2 Eli Lilly Business Overview
- 6.7.3 Eli Lilly Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Eli Lilly Anti Obesity Drugs Product Portfolio
- 6.7.5 Eli Lilly Recent Developments
- 6.8 VIVUS
- 6.8.1 VIVUS Company Information
- 6.8.2 VIVUS Business Overview
- 6.8.3 VIVUS Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 VIVUS Anti Obesity Drugs Product Portfolio
- 6.8.5 VIVUS Recent Developments
- 6.9 Pharscin Pharma
- 6.9.1 Pharscin Pharma Company Information
- 6.9.2 Pharscin Pharma Business Overview
- 6.9.3 Pharscin Pharma Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Pharscin Pharma Anti Obesity Drugs Product Portfolio
- 6.9.5 Pharscin Pharma Recent Developments
- 6.10 Novo Nordisk
- 6.10.1 Novo Nordisk Company Information
- 6.10.2 Novo Nordisk Business Overview
- 6.10.3 Novo Nordisk Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Novo Nordisk Anti Obesity Drugs Product Portfolio
- 6.10.5 Novo Nordisk Recent Developments
- 6.11 Lupin Laboratories
- 6.11.1 Lupin Laboratories Company Information
- 6.11.2 Lupin Laboratories Business Overview
- 6.11.3 Lupin Laboratories Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Lupin Laboratories Anti Obesity Drugs Product Portfolio
- 6.11.5 Lupin Laboratories Recent Developments
- 6.12 iNova Pharmaceuticals
- 6.12.1 iNova Pharmaceuticals Company Information
- 6.12.2 iNova Pharmaceuticals Business Overview
- 6.12.3 iNova Pharmaceuticals Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 iNova Pharmaceuticals Anti Obesity Drugs Product Portfolio
- 6.12.5 iNova Pharmaceuticals Recent Developments
- 6.13 Hypera Pharma
- 6.13.1 Hypera Pharma Company Information
- 6.13.2 Hypera Pharma Business Overview
- 6.13.3 Hypera Pharma Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Hypera Pharma Anti Obesity Drugs Product Portfolio
- 6.13.5 Hypera Pharma Recent Developments
- 6.14 GlaxoSmithKline
- 6.14.1 GlaxoSmithKline Company Information
- 6.14.2 GlaxoSmithKline Business Overview
- 6.14.3 GlaxoSmithKline Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 GlaxoSmithKline Anti Obesity Drugs Product Portfolio
- 6.14.5 GlaxoSmithKline Recent Developments
- 6.15 Alvogen
- 6.15.1 Alvogen Company Information
- 6.15.2 Alvogen Business Overview
- 6.15.3 Alvogen Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Alvogen Anti Obesity Drugs Product Portfolio
- 6.15.5 Alvogen Recent Developments
7 North America
- 7.1 North America Anti Obesity Drugs Market Size (2021-2032)
- 7.2 North America Anti Obesity Drugs Market Size by Type
- 7.2.1 North America Anti Obesity Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Anti Obesity Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Anti Obesity Drugs Market Share by Type (2021-2032)
- 7.3 North America Anti Obesity Drugs Market Size by Application
- 7.3.1 North America Anti Obesity Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Anti Obesity Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Anti Obesity Drugs Market Share by Application (2021-2032)
- 7.4 North America Anti Obesity Drugs Market Size by Country
- 7.4.1 North America Anti Obesity Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Anti Obesity Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Anti Obesity Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Anti Obesity Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Anti Obesity Drugs Market Size (2021-2032)
- 8.2 Europe Anti Obesity Drugs Market Size by Type
- 8.2.1 Europe Anti Obesity Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Anti Obesity Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Anti Obesity Drugs Market Share by Type (2021-2032)
- 8.3 Europe Anti Obesity Drugs Market Size by Application
- 8.3.1 Europe Anti Obesity Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Anti Obesity Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Anti Obesity Drugs Market Share by Application (2021-2032)
- 8.4 Europe Anti Obesity Drugs Market Size by Country
- 8.4.1 Europe Anti Obesity Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Anti Obesity Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Anti Obesity Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Anti Obesity Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Anti Obesity Drugs Market Size (2021-2032)
- 9.2 China Anti Obesity Drugs Market Size by Type
- 9.2.1 China Anti Obesity Drugs Market Size by Type (2021-2026)
- 9.2.2 China Anti Obesity Drugs Market Size by Type (2027-2032)
- 9.2.3 China Anti Obesity Drugs Market Share by Type (2021-2032)
- 9.3 China Anti Obesity Drugs Market Size by Application
- 9.3.1 China Anti Obesity Drugs Market Size by Application (2021-2026)
- 9.3.2 China Anti Obesity Drugs Market Size by Application (2027-2032)
- 9.3.3 China Anti Obesity Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Anti Obesity Drugs Market Size (2021-2032)
- 10.2 Asia Anti Obesity Drugs Market Size by Type
- 10.2.1 Asia Anti Obesity Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Anti Obesity Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Anti Obesity Drugs Market Share by Type (2021-2032)
- 10.3 Asia Anti Obesity Drugs Market Size by Application
- 10.3.1 Asia Anti Obesity Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Anti Obesity Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Anti Obesity Drugs Market Share by Application (2021-2032)
- 10.4 Asia Anti Obesity Drugs Market Size by Country
- 10.4.1 Asia Anti Obesity Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Anti Obesity Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Anti Obesity Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Anti Obesity Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Anti Obesity Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Anti Obesity Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Anti Obesity Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Anti Obesity Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Anti Obesity Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Anti Obesity Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Anti Obesity Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Anti Obesity Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Anti Obesity Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Anti Obesity Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Anti Obesity Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Anti Obesity Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Anti Obesity Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Anti Obesity Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst